Form 4: Slim Family Increases Stake in ProKidney Corp. Through Market Purchases
SEC Form 4 Filing
Control Empresarial de Capitales S.A. de C.V., associated with the Slim Family, has increased its holdings in ProKidney Corp. through open market purchases of Class A Ordinary Shares.
Summary
- Control Empresarial de Capitales S.A. de C.V., a company associated with the Slim Family, has reported changes in its beneficial ownership of ProKidney Corp. shares.
- On April 14, 2025, Control Empresarial purchased 268,105 Class A Ordinary Shares at a weighted average price of $0.7258.
- On April 15, 2025, the company purchased an additional 468,000 Class A Ordinary Shares at a weighted average price of $0.6966.
- Following these transactions, Control Empresarial beneficially owns 73,330,330 shares, including 63,118,645 Class B Ordinary Shares.
- The Slim Family, as beneficiaries of a Mexican trust that owns Control Empresarial, may be deemed to indirectly beneficially own these shares.
- Collectively, the shares beneficially owned by Control Empresarial represent approximately 25.1% of ProKidney Corp.'s total outstanding shares.
- The total outstanding shares are comprised of 129,536,121 Class A Ordinary Shares and 163,161,528 Class B Ordinary Shares, as per the company's Form 10-K filed on March 17, 2025.
Sentiment
Score: 6
Explanation: The sentiment is neutral. The document simply reports transactions. Increased ownership by a major shareholder could be interpreted as a positive signal, but without more context, it's difficult to draw strong conclusions.
Positives
- Increased investment by a major shareholder could signal confidence in the company's future prospects.
Risks
- The document does not provide any specific information about the company's performance or future plans, making it difficult to assess the overall investment risk.
Industry Context
Form 4 filings are routine disclosures of transactions by company insiders and major shareholders. They provide transparency into the buying and selling activities of those with privileged information, but do not necessarily indicate a change in the company's strategic direction.
Stakeholder Impact
- The increased stake by the Slim Family could be viewed positively by shareholders, potentially increasing investor confidence.
Key Dates
| Date | Description |
|---|---|
| January 18, 2022 | Date of the Business Combination Agreement between the issuer and ProKidney LP. |
| February 3, 2022 | Date of Schedule 13D/A filing by the Slim Family and Control Empresarial with the SEC. |
| June 10, 2022 | Date of the issuer's Definitive Proxy Statement filed with the SEC. |
| March 17, 2025 | Date of the Issuers Form 10-K filed with the SEC. |
| April 14, 2025 | Date of first transaction: Purchase of 268,105 Class A Ordinary Shares. |
| April 15, 2025 | Date of second transaction: Purchase of 468,000 Class A Ordinary Shares. |
| April 16, 2025 | Date of signature of the Form 4 filing. |
Keywords
ProKidney Corp, Control Empresarial, Slim Family, Class A Ordinary Shares, Class B Ordinary Shares, Beneficial Ownership, SEC Form 4
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.